Registration
|
08:15 - 08:50 |
Welcome note from MarketsandMarkets
|
08:50 - 08:55 |
Opening remarks from the Chairman
Allan Stensballe, Associate Professor, Aalborg University
|
08:55 - 09:00 |
CLINICAL BIOMARKER DRUG DEVELOPMENT AND PRECISION MEDICINE |
Aligning Innovation with Precision Medicine
Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca
|
09:00 - 09:35 |
Gene expression signatures: key success factors
Eike Staub, Head of Oncology Data Science, Merck Healthcare, Germany
|
09:35 - 10:10 |
Transforming Oncology with Predicine’s Liquid Biopsy Solutions
Shidong Jia, Founder, CEO, Predicine
|
10:10 - 10:45 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:45 - 11:30 |
DNA Methylation: Potential Surrogate Endpoint Biomarkers in Drug Development and Clinical Trails
|
11:30 - 12:05 |
Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions
Louis Boon, CSO and Board Member, JJP Biologics
|
12:05 - 12:40 |
Precision Proteomic Landscape of health-to-disease transitions of Rheumatic Musculoskeletal disorders and links to Cancer associate irAEs
Allan Stensballe, Associate Professor, Aalborg University
|
12:40 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meeting
|
13:15 - 14:15 |
Why do 95% of oncology drugs fail in clinical development, and how can biomarkers help?
Philip Beer, Chief Scientific Officer, Step Pharma
|
14:15 - 14:50 |
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics
Illip Burmester, Technical and Applications Manager, Proteome Sciences
|
14:50 - 15:25 |
When over 99% of published Biomarkers end up in the bin what can we do to reduce this waste and pick out the ones that could be rescued?
Christopher Peters, Clinical Senior Lecturer, Imperial College London
|
15:25 - 00:00 |
Evening Refreshments and Poster Presentation | One-to-One Networking Meetings
|
16:00 - 16:45 |
Panel Discussion: Clinical biomarker development is critical to bring precision medicine from a scientific concept into clinical practice-Views?
Louis Boon, CSO and Board Member, JJP Biologics
Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca
Vaios Karanikas, Biomarker Experimental Medicine Leader, Oncology, Roche
Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby
Christopher Peters, Clinical Senior Lecturer, Imperial College London
|
16:45 - 00:00 |
Closing Remarks from the Chairperson
|
17:20 - 17:20 |
Drinks Reception & Networking
|
17:20 - 17:20 |
End of Day 1
|
17:20 - 17:20 |